title: [Combination therapy with insulin/sulfonylurea in the long-term therapy of type II diabetes following "secondary failure"].
abstract: In type 2 diabetes with "secondary failure of sulfonylurea therapy" good metabolic control can seldom be achieved by insulin therapy even with high insulin doses. Hyperinsulinemia however is a possible risk factor of cardiovascular disease in type 2 diabetes. Maintaining the effects of sulfonylurea action insulin should be added in as small amounts as possible to avoid hyperinsulinemia and to ameliorate hyperglycemia. 16 type 2 diabetics with "secondary failure" were treated either with insulin alone (group A; n = 8) or with 3.5 mg b.i.d. glibenclamide plus small amounts of intermediate insulin (group B; n = 8) in a randomised order. After the inpatient period outpatient control was performed monthly up to six months, later on four times a year up to two years. Both groups were comparable with regard to age, duration of diabetes, body weight and metabolic control. The daily insulin dose was 14 +/- 2 IU (means +/- SEM) after one month and 19 +/- 2 IU after two years in group B. In contrast 30 +/- 3 IU and 43 +/- 5 IU respectively were needed in group A (p less than 0.001). All patients B were treated with one daily injection, all patients A needed two injections. Resulting in nearly identical metabolic control in group A basal insulin levels exceeded those in group B after two years significantly (28.6 +/- 3.7 vs. 18.6 +/- 1.6 mcU/ml; p less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: III. Medizinische Abteilung Städtisches Krankenhaus München-Schwabing, München.
authors.forename: N
authors.initials: N
authors.lastname: Lotz
authors.forename: W
authors.initials: W
authors.lastname: Bachmann
authors.forename: T
authors.initials: T
authors.lastname: Ladik
authors.forename: H
authors.initials: H
authors.lastname: Mehnert
mesh_terms: D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000378:metabolism; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005905:Glyburide / Q000008:administration & dosage*; D006801:Humans; D007328:Insulin / Q000008:administration & dosage* / Q000097:blood; D008875:Middle Aged
chemical_list: D001786:Blood Glucose; D007328:Insulin; D005905:Glyburide
vernacular_title: Die Kombinationstherapie Insulin/Sulfonylharnstoff in der Langzeittherapie des Typ-II-Diabetes nach "Sekundärversagen".